CN114650866B - 新的用于诊断的分子 - Google Patents

新的用于诊断的分子

Info

Publication number
CN114650866B
CN114650866B CN202080077792.6A CN202080077792A CN114650866B CN 114650866 B CN114650866 B CN 114650866B CN 202080077792 A CN202080077792 A CN 202080077792A CN 114650866 B CN114650866 B CN 114650866B
Authority
CN
China
Prior art keywords
seq
amino acid
amyloid
acid sequence
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080077792.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN114650866A (zh
Inventor
奥斯卡·阿道夫松
卡塔日娜·埃娃·皮奥尔科夫斯卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AC Immune SA
Original Assignee
AC Immune SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AC Immune SA filed Critical AC Immune SA
Publication of CN114650866A publication Critical patent/CN114650866A/zh
Application granted granted Critical
Publication of CN114650866B publication Critical patent/CN114650866B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
CN202080077792.6A 2019-09-10 2020-09-10 新的用于诊断的分子 Active CN114650866B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19196512 2019-09-10
EP19196512.8 2019-09-10
EP20184340.6 2020-07-06
EP20184340 2020-07-06
PCT/EP2020/075420 WO2021048324A1 (en) 2019-09-10 2020-09-10 Novel molecules for diagnosis

Publications (2)

Publication Number Publication Date
CN114650866A CN114650866A (zh) 2022-06-21
CN114650866B true CN114650866B (zh) 2025-08-01

Family

ID=72356005

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080077792.6A Active CN114650866B (zh) 2019-09-10 2020-09-10 新的用于诊断的分子

Country Status (10)

Country Link
US (1) US20230034474A1 (cg-RX-API-DMAC7.html)
EP (1) EP4028127A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022547993A (cg-RX-API-DMAC7.html)
KR (1) KR20220087439A (cg-RX-API-DMAC7.html)
CN (1) CN114650866B (cg-RX-API-DMAC7.html)
AU (1) AU2020347483A1 (cg-RX-API-DMAC7.html)
CA (1) CA3149837A1 (cg-RX-API-DMAC7.html)
IL (1) IL291224A (cg-RX-API-DMAC7.html)
MX (1) MX2022002873A (cg-RX-API-DMAC7.html)
WO (1) WO2021048324A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4649091A2 (en) * 2023-01-12 2025-11-19 University Of Virginia Patent Foundation Anti-cith3 antibodies and uses thereof
WO2025134068A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Antibody drug conjugates targeting proteinopathies, and uses thereof
CN117567635B (zh) * 2024-01-16 2024-05-14 恺佧生物科技(上海)有限公司 抗Cas9酶的抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101802007A (zh) * 2007-06-12 2010-08-11 Ac免疫有限公司 抗β淀粉样蛋白单克隆抗体
CN102762220A (zh) * 2007-10-15 2012-10-31 森托科尔奥索生物科技公司 人抗淀粉样蛋白抗体、组合物、方法和用途发明背景

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068316A1 (en) * 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
KR20070094890A (ko) * 2004-10-25 2007-09-27 머크 앤드 캄파니 인코포레이티드 안티 addl 항체 및 그 용도
KR20100115340A (ko) * 2007-10-19 2010-10-27 이무나스 파마 가부시키가이샤 Aβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용
CN102596997B (zh) * 2009-08-06 2015-06-03 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
EP2632434B1 (en) * 2010-10-26 2025-08-20 AC Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101802007A (zh) * 2007-06-12 2010-08-11 Ac免疫有限公司 抗β淀粉样蛋白单克隆抗体
CN102762220A (zh) * 2007-10-15 2012-10-31 森托科尔奥索生物科技公司 人抗淀粉样蛋白抗体、组合物、方法和用途发明背景

Also Published As

Publication number Publication date
WO2021048324A9 (en) 2022-05-05
KR20220087439A (ko) 2022-06-24
CA3149837A1 (en) 2021-03-18
EP4028127A1 (en) 2022-07-20
US20230034474A1 (en) 2023-02-02
JP2022547993A (ja) 2022-11-16
WO2021048324A1 (en) 2021-03-18
AU2020347483A1 (en) 2022-03-31
CN114650866A (zh) 2022-06-21
MX2022002873A (es) 2022-03-25
IL291224A (en) 2022-05-01
JP2025178565A (ja) 2025-12-08

Similar Documents

Publication Publication Date Title
JP7399096B2 (ja) 神経変性を検出するためのアッセイ
CN108034005B (zh) 识别Tau的磷酸化特异抗体
JP7837375B2 (ja) ピログルタメートアミロイド-βに対する抗体及びその使用
KR101616136B1 (ko) Aβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용
CN112236452A (zh) 检测和治疗阿尔茨海默氏病的基于抗体的方法
JP2017512056A (ja) ヒト・タウに結合する抗体および該抗体を使用してヒト・タウを定量するためのアッセイ
JP2025178565A (ja) 診断のための新規分子
CN106659759A (zh) 人源化抗tau抗体
CN101965365A (zh) 能够特异性结合Aβ寡聚体的抗体及其应用
CA2812865A1 (en) Phosphospecific antibodies recognising tau
KR20210154179A (ko) 치료 및 진단용 신규한 분자
KR20180118151A (ko) 다발성 골수종에서 m-단백질 반응의 임상 평가
KR102509648B1 (ko) 병리학적 타우 종에 결합하는 항체 및 이의 용도
HK40068370A (en) Novel molecules for diagnosis
CN115210256A (zh) 用于前列腺癌诊断的新方法和化合物
KR20160093503A (ko) 항 crs 모노클로날 항체 및 이의 용도
KR102688094B1 (ko) Cobll1 단백질 특이 항체 또는 이의 항원 결합 단편, 및 이의 용도
WO2026074330A1 (en) Antibodies and diagnostic methods for detecting bag3 protein in clinical samples
EA045911B1 (ru) АНТИТЕЛА К ПИРОГЛУТАМАТ-β-АМИЛОИДУ И ИХ ПРИМЕНЕНИЕ

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40068370

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant